REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material > Monoclonal Antibody Or Fragment Thereof (i.e., Produced By Any Cloning Technology) Monoclonal Antibody Or Fragment Thereof (i.e., Produced By Any Cloning Technology)Monoclonal Antibody Or Fragment Thereof (i.e., Produced By Any Cloning Technology) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.07/19/07 - 20070166306 - Anti-cd19 antibody composition and method A method of enhancing the antibody-dependent cellular cytotoxicity (ADCC) of a human or humanized CD19 antibody is disclosed. The antibody is produced in the presence of a beta.(1,4)-N-acetylglucosaminyltransferase III (GnTIII) enzyme, under conditions effective to produce in the antibody, an Fc fragment characterized by Asn297-linked oligosaccharides containing (i) at least ... 06/14/07 - 20070134236 - Humanized antibodies against monocyte chemotactric proteins The invention provides humanized antibodies that bind to a plurality of b-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides therapeutic reagents and methods of treating disorders associated with detrimental MCP activity. ... 05/31/07 - 20070122404 - Humanized immunoglobulin reactive with alpha4beta7 integrin The present invention relates to a humanized immunoglobulin that has binding specificity for α4β7 integrin and comprises the complementarity determining regions (CDRs) of mouse Act-1 antibody, and to the humanized light chain of the humanized immunoglobulin. The present invention further relates to a humanized immunoglobulin light chain. The invention also ... 04/05/07 - 20070077243 - Method for making humanized antibodies Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided. ... 02/08/07 - 20070031405 - Use of a33 antigens and jam-it The present invention relates to compositions and methods of treating and diagnosing disorders characterized the by the presence of antigens associated with inflammatory diseases and/or cancer. ... 02/08/07 - 20070031404 - Antibodies Nucleic acids encoding SOC/CRAC calcium channel polypeptides, including fragments and biologically functional variants thereof and encoded polypeptides are provided. The nucleic acids and polypeptides disclosed herein are useful as therapeutic and diagnostic agents. Agents that selectively bind to the foregoing polypeptides and genes also are provided. ... 01/25/07 - 20070020261 - Combination therapy of her expressing tumors The invention relates to tumors expressing HER2 and EGFR, using HER2-dimerization inhibitors (HDIs) and EGFR inhibitors. ... 01/04/07 - 20070003547 - Super humanized antibodies Disclosed herein are methods for humanizing antibodies based on selecting variable region framework sequences from human antibody genes by comparing canonical CDR structure types for CDR sequences of the variable region of a non-human antibody to canonical CDR structure types for corresponding CDRs from a library of human antibody sequences, ... 12/28/06 - 20060292140 - Humanized immunoglobulin reactive with alpha4beta7 integrin The present invention relates to humanized immunoglobulins having binding specificity for α4β7 integrin, comprising an antigen binding region of nonhuman origin (e.g., rodent) and at least a portion of an immunoglobulin of human origin (e.g., a human framework region, a human constant region). In one embodiment, the humanized immunoglobulin can ... 12/21/06 - 20060286101 - Use of cd23 antagonists for the treatment of neoplastic disorders Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL). ... 12/21/06 - 20060286100 - Use of cd23 antagonists for the treatment of neoplastic disorders Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL). ... 12/14/06 - 20060280738 - Anti-cd19 antibody therapy for transplantation The invention relates to immunotherapeutic compositions and methods for the treatment and prevention of GVHD, humoral rejection, and post-transplantation lymphoproliferative disorder in human subjects using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or ... 12/14/06 - 20060280737 - Wsx receptor agonist antibodies Methods for identifying antibodies that decrease body weight, fat depot weight or food intake in an obese animal are provided, as well as antibodies. Preferred antibodies bind to a reactor having a WSX motif and the extracellular domain sequence within SEQ ID NO:2. ... 11/23/06 - 20060263355 - Treatment of bone disorders Methods of treatment of various bone indications, such as osteoporosis, in a mammal are provided wherein an effective amount of an antagonist that binds to a B-cell surface marker, such as a CD20 antibody, is administered, optionally also with another medicament such as an agent that treats such disorders in ... 11/16/06 - 20060257398 - Anti-cd19 antibodies The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. ... 11/16/06 - 20060257397 - Human binding molecule against cd1a The present invention provides human binding molecules that specifically bind to CD1a, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prevention and treatment of ... 11/16/06 - 20060257396 - Abeta antibodies for use in improving cognition The invention provides improved agents and methods for treatment of diseases associated with beta amyloid (Aβ). Preferred agents include antibodies, e.g., humanized antibodies specific for Aβ. ... 11/09/06 - 20060251645 - Humanized immunoglobulin reactive with b7-2 and methods of treatment therewith The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 ... 11/02/06 - 20060246061 - Method for generating monoclonal antibodies Methods for generating monoclonal antibodies in Th1-biased rodents are disclosed. The monoclonal antibodies are useful as therapeutic agents, diagnostic agents or research reagents. ... 11/02/06 - 20060246060 - Novel stable formulation Invented are non-peptide TPO mimetics. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative. ... 10/26/06 - 20060240003 - Humanised antibodies to the epidermal growth factor receptor The present invention provides a humanised form of the antibody 340 obtainable from the cell line deposited with the ECACC under accession number 97021428. Such antibodies have been found to have an increased ability to kill cells compared to the murine antibody 340. Also provided are nucleic acids encoding such ... 10/26/06 - 20060240002 - Methods of inhibiting angiogenesis-dependent conditions mediated by cryptic epitopes of extracellular matrix components The invention provides methods for identifying genes and proteins modulated by an antagonist to a cryptic epitope of an ECM component that specifically binds to the ECM component. It additionally provides methods for using the products of the identified genes, or for using the identified proteins, for inhibiting angiogenesis, tumor ... 10/19/06 - 20060233791 - Anti-cd19 antibodies and uses in oncology The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to ... 10/19/06 - 20060233790 - Immunoglobulin/hydrophilic peptide complexes The present invention provides an immunoglobulin preparation comprising an immunoglobulin-hydrophilic peptide complex in which an immunoglobulin and a hydrophilic peptide are linked optionally via a divalent group, and a pharmacologically acceptable carrier. The immunoglobulin preparation has cell permeability, or in other words, it can penetrate through a cell membrane and ... 10/12/06 - 20060228352 - Trail and methods of modulating t cell activity and adaptive immune responses using trail Methods of modulating a T cell response are provided. Methods include, among other things, contacting a T cell that expresses TNF-related apoptosis-inducing ligand (TRAIL, Apo-2L) or TRAIL receptor (DR4 or DR5) with a molecule that binds to TRAIL (Apo-2L), a molecule that binds to TRAIL receptor (DR4 or DR5), or ... 10/12/06 - 20060228351 - Method of inducing differentiation and proliferating regulatory t cell by anti-cd52 antibody and medicinal composition therefor An object of the present invention is to provide a method for inducing differentiation and/or promoting proliferation of regulatory T cells, a method for suppressing the transendothelial cell migration of immunocytes, a method for suppressing immunity using these methods, and a pharmaceutical composition to be used for these methods. Provided ... 10/05/06 - 20060222644 - Humanized anti-lymphotoxin beta receptor antibodies This invention concerns humanized antibodies specific for the lymphotoxin beta receptor (LT-β-R), cell lines that produce these antibodies, immunochemicals made from the antibodies, and diagnostic methods that use the antibodies. The invention also relates to the use of the antibodies alone or in combination with chemotherapeutic agent(s) in therapeutic methods. ... 10/05/06 - 20060222643 - Anti-mpl antibody Anti-human Mpl antibodies were isolated and purified, and then anti-human Mpl diabodies and anti-human Mpl sc(Fv)2 were purified using genetic engineering techniques. Furthermore, the present inventors succeeded in humanizing anti-human Mpl sc(Fv)2. The diabodies and sc(Fv)2 were assayed for TPO-like agonistic activity, and were found to have activities higher than ... 07/27/06 - 20060165682 - Humanized antibodies that recognize beta amyloid peptide The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include antibodies, e.g., humanized antibodies. ... 06/08/06 - 20060121028 - Variant igg3 rituxan and therapeutic uses thereof Monoclonal anti-human CD20 antigen binding antibodies containing human IgG3 constant domains are provided. These antibodies possess effector functions that render them well suited for use in therapeutic methods, especially treatments wherein inhibition of B cell function or B cell number is therapeutically desirable. ... 04/06/06 - 20060073144 - Individualized anti-cancer antibodies The present invention relates to a method for producing patient specific anti-cancer antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies customized for the individual patient that can be used ... 03/30/06 - 20060067932 - Antagonists specific for denatured collagen and methods of using same The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen but not to native triple helical forms of the collagen. Antagonists of the invention can target, for example, denatured collagens type-I, type-II, type-III, type-IV, type-V and combinations ... 03/23/06 - 20060062784 - Compositions monovalent for cd40l binding and methods of use The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of CD40L. In one aspect, a monovalent anti-CD40L antibody polypeptide consists ... 03/23/06 - 20060062783 - Antibodies against parathyroid hormone Embodiments of the invention described herein relate to antibodies directed to the antigen parathyroid hormone (PTH) and uses of such antibodies. In particular, in some embodiments, there are provided fully human monoclonal antibodies directed to the antigen PTH. In further embodiments, nucleotide sequences encoding, and amino acid sequences comprising, heavy ... 03/09/06 - 20060051352 - Cea binding agents and compositions to reverse cea-mediated tumorigenic effects on human cancer cells, restore sensitivity to drug induced apoptosis and uses thereof The present invention relates to differentiation, apoptosis and tumorigenicity. The present invention more particularly relates to compositions comprising ligands which target CEA such that the adhesion, differentiation-Inhibitory and apoptosis-resistance activities (tumorigenic effects) of Ig superfamily member, CEA, can be reduced or blocked. More particularly, the present invention relates to CEA-binding ... 02/23/06 - 20060039906 - Humanized antibodies that sequester abeta peptide A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble Aβ peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide Aβ. ... 02/16/06 - 20060034838 - Anti-human vegf receptor flt-1 monoclonal antibody The present invention provides an antibody or peptide which immunologically reacts with human VEGF receptor Flt-1 and cells in which human VEGF receptor Flt-1 is expressed on the cell surface and an antibody or peptide which inhibits binding of human VEGF to human VEGF receptor Flt-1. It also provides a ... 02/02/06 - 20060024303 - Targeting and prolonging association of drugs to the luminal surface of the pulmonary vascular endothelial cells Methods for targeting and prolonging association of a selected drug to the luminal surface of pulmonary vascular endothelium of an animal are provided wherein a selected drug is administered to an animal in combination with a non-internalizable antibody which binds to an antigen on the luminal surface of the pulmonary ... 02/02/06 - 20060024302 - Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same The present invention relates to materials and methods for modulating angiogenesis and lymphangiogenesis. The compositions of the invention provide chimeric and/or humanized VEGF-D antibody substances, antibodies, polypeptides and fragments thereof useful for modulating angiogenesis and lymphangiogenesis in a subject. ... 01/19/06 - 20060013813 - Proteins and nucleic acids encoding same Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research ... 01/05/06 - 20060002922 - Method for preventing or treating obesity by modulating the activities of the pentose phosphate patway Method for preventing or treating overweight or obesity, the method comprising administering to a patient in need thereof an antagonist that inhibits gene expression or activity of an enzyme that is involved or related to the pentose phosphate pathway. Preferably, the enzyme is a transketolase, and the antagonist is an ... 01/05/06 - 20060002921 - Optimized dosing with anti-cd4 antibodies for tolerance induction in primates The present invention is based, at least in part, on the finding that tolerance can be induced by inhibition of CD4+ cells (and optionally CD8+ cells). Accordingly, the optimized dosing methods of the invention are useful in treating a primate, e.g., a human, by inhibiting CD4+ T cells to induce ... 12/29/05 - 20050287137 - Novel composition The present invention relates to novel therapies and treatments of atherosclerotic diseases. Accordingly there is provided, methods of treating or preventing atherosclerosis by passive vaccination through administration to a patient of a fully human antibody that is capable of binding to the specific fragments of ApoCIII. Specific human monoclonal antibodies ... 12/29/05 - 20050287136 - Human monoclonal antibodies to ctla-4 In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within ... 12/22/05 - 20050281811 - Anti-lymphotoxin-beta receptor antibodies as anti-tumor agents This invention relates to compositions and methods useful for activating LT-β receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin-α and multiple subunits of lymphotoxin-β, which induce cytotoxic effects on tumor cells in the presence ... 12/22/05 - 20050281810 - Variants of alternative splicing The present invention concerns novel variants produced by alternative splicing of known genes, amino acid sequences of the variants as well as their uses in detection and therapy. ... 12/15/05 - 20050276803 - Method for augmenting b cell depletion The present invention provides methods of augmenting B cell depletion by promoting intravascular access of B cell subsets sequestered in lymphoid tissues rendering the B cells sensitive to killing mediated by the B cell depleting agent. One method of promoting intravascular access is by the use of integrin antagonists. Methods ... 12/15/05 - 20050276802 - Humanized anti-tgf-beta antibodies Humanized anti-TGF-beta antibodies are provided, as well as methods for their preparation and use, including methods for treating TGF-beta disorders, for example, cancer. Also provided are articles of manufacture designed for various uses that contain the humanized antibodies. ... 12/15/05 - 20050276801 - Method of treatment using humanized anti-cd11a antibodies Humanized anti-CD11a antibodies and various uses therefor are disclosed. The humanized anti-CD11a antibody may bind specifically to human CD11a I-domain, have an IC50(nM) value of no more than about 1 nM for preventing adhesion of Jurkat cells to normal human epidermal keratinocytes expressing ICAM-1, and/or an IC50 (nM) value of ... 12/08/05 - 20050271654 - Antibody purification A process for purifying an antibody is provided. In this process, a mixture containing the antibody and a contaminant is subjected to low pH hydrophobic interaction chromatography (LPHIC) at low salt concentration. The antibody is eluted from the column in the fraction which does not bind thereto. This process can ... 12/01/05 - 20050265997 - Cancer treatment method by inhibiting mage gene expression or function Method for inhibiting tumor cell formation or tumor cell growth, and method for inducing apoptosis in sperms, the method comprising administering to a patient in need thereof an antagonist that inhibits MAGE gene expression or MAGE protein function. Preferably, the antagonist is an anti-MAGE antibody, an antisense molecule, an siRNA ... 12/01/05 - 20050265996 - Method and system to remove soluble tnfr1, tnfr2, and il2 in patients A method, and system, to induce remission in diseases characterized by excess production of sTNR and interleukin 2 has been developed. In the most preferred embodiment, the system consists of antibodies to sTNFR1, sTNFR2 and sIL2R immobilized in a column containing a material such as SEPHAROSE™. The patient is connected ... 12/01/05 - 20050265995 - Tissue targeted complement modulators Systemic suppression of the complement system has been shown to be effective to treat inflammatory disease, yet at the potential cost of compromising host defense and immune homeostasis. Herein disclosed are methods for antigen-specific targeting of complement inhibitors that show that complement inhibitors targeted to the proximal tubular epithelium protect ... 12/01/05 - 20050265994 - Methods for treating bone cancer pain by administering a nerve growth factor antagonist The invention features methods and compositions for preventing or treating bone cancer pain including cancer pain associated with bone metastasis by administering an antagonist of nerve growth factor (NGF). The NGF antagonist may be an anti-NGF (such as anti-hNGF) antibody that is capable of binding hNGF. ... 12/01/05 - 20050265993 - Methods of treating autoimmune and inflammatory diseases This invention provides method of treatment of autoimmune diseases and/or inflammatory disorders. ... 11/24/05 - 20050260196 - Method of treating cancer and identifying novel anti-cancer compounds The present invention relates to compositions and methods for treating cancer, especially epithelial and eutopic cancers using inhibitors of H-HCG or β-H-HCG, as well as vaccines for use in oncostasis or reducing the likelihood of recurrence of cancer after remission. In addition, the present invention provides a method for reducing ... 11/24/05 - 20050260195 - Treatment of hepatitis b virus infection with human monoclonal antibodies Disclosed is a pharmaceutical composition for the treatment or prevention of hepatitis B virus infection, comprising a 1:3 mixture of two fully human anti HBsAg monoclonal antibodies 19.79.5 and 17.1.41. Also disclosed are preferred modes of administration. The pharmaceutical composition can be given as a monotherapy or in combination with ... 11/17/05 - 20050255100 - Antibodies to tumor necrosis factor receptor 5 The present invention relates to a novel human gene encoding a polypeptide which is a member of the TNF receptor family, and has now been found to bind TRAIL. More specifically, an isolated nucleic acid molecule is provided encoding a human polypeptide named tumor necrosis factor receptor-5, sometimes referred to ... 11/10/05 - 20050249728 - Anti-igf-i receptor antibody Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit, insulin-like growth factor-I receptor, antagonize the effects of IGF-I, IGF-II and serum on the growth and survival of tumor cells, and which are substantially devoid of agonist activity. ... 11/10/05 - 20050249727 - Prevention and treatment of amyloidogenic disease The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is ... 11/10/05 - 20050249726 - Reshaped human antibody to human medulloblastoma cells The present invention discloses reshaped antibody to human medulloblastoma cells comprising: (A) an L chain comprising: (1) a human L chain C region, and (2) an L chain V region comprising human L chain FRs and L chain CDRs of mouse monoclonal antibody ONS-M21 to human medulloblastoma cells; and, (B) ... 11/10/05 - 20050249725 - Humanized antibodies that recognize beta amyloid peptide The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies. ... 11/03/05 - 20050244405 - Vascular endothelial cell growth factor antagonists and uses thereof The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF antagonists are also provided. ... 10/27/05 - 20050238642 - Modified bouganin proteins, cytotoxins and methods and uses thereof The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate ... 10/20/05 - 20050232917 - Antibodies to madcam The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to MAdCAM, preferably human MAdCAM and that function to inhibit MAdCAM. The invention also relates to human anti-MAdCAM antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, ... 10/13/05 - 20050226866 - Chordin-like molecules and uses thereof The present invention provides Chordin-Like (CHL) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing CHL polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions ... 10/13/05 - 20050226865 - Methods and compositions for treating and preventing diseases associated with alphavbeta5 integrin The present invention provides compositions and methods for treating and preventing disease associated with αvβ5 integrin by blocking binding to αvβ5 integrin. ... 10/06/05 - 20050220786 - Lyophilised preparation comprising antibodies against the efg receptor The invention relates to a lyophilised pharmaceutical preparation comprising an antibody against the endothelial growth factor receptor (EGF receptor). The preparation has increased storage stability, even at elevated temperatures, and, after reconstitution, can be used parenterally for the treatment of tumours. ... 09/29/05 - 20050214280 - Method for inhibiting tumor formation and growth Method for inhibiting tumor cell formation or tumor cell growth, the method comprising administering to a patient in need thereof an antagonist to VEGF-B. Preferably, the antagonist is an anti-VEGF-B antibody, an antisense molecule, an RNAi molecule, a molecule for forming a triplex nucleic acid molecule with a VEGF-B encoding ... 09/29/05 - 20050214279 - Methods for stimulating human leukocytes to kill bacteria, yeast and fungi in biofilms that have formed in/on prosthetic devices, catheters, tissues and organs in vivo The present invention provides a method for stimulating human leukocytes to kill microorganisms in biofilms. The invention also provides a methods, compositions and kits for treating or preventing a biofilm infection in a mammal comprising administering a therapeutically effective amount of a complement protein and one or more antibodies which ... 09/22/05 - 20050208043 - Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies. ... 09/22/05 - 20050208042 - Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering ... 09/22/05 - 20050208041 - Humanized antibodies to interferon alpha receptor-1 (ifnar-1) Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies. ... 09/01/05 - 20050191292 - Prevention and treatment of amyloidogenic disease The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is ... 08/25/05 - 20050186202 - Variants of humanized anti-carcinoma monoclonal antibody cc49 The invention is directed towards mouse-human chimeric variants of CC49 monoclonal antibodies with minimal murine content. A first aspect of the invention provides CDR variants of humanized monoclonal antibody (HuCC49) in which less than all six (three heavy chain and three light chain) Complementarity Determining Regions (CDRs) of CC49 are ... 08/18/05 - 20050180969 - Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from cancer. ... 08/04/05 - 20050169916 - Treatment of lfa-1 associated disorders with increasing doses of lfa-1 antagonist A method is provided for reducing the occurrence of fever, headache, nausea and/or vomiting associated with administration of a therapeutic compound to a mammal in need thereof, comprising administering to the mammal a first conditioning dose of a non-target cell depleting compound which binds to a cell surface receptor on ... 08/04/05 - 20050169915 - Recombinant peptides derived from the mc3 anti-ba46 antibody, methods of use thereof, and methods of humanizing antibody peptides The present invention provides recombinant peptides that specifically and selectively bind to the human milk fat globule (HMFG) antigen, BA46. In particular, the present invention provides recombinant variants of the Mc3 antibody, including humanized versions of Mc3. The variant Mc3 peptides are particularly useful for diagnostic, prognostic, and therapeutic applications ... 07/28/05 - 20050163772 - B7s1: an immune modulator The invention provides B7S1 nucleic acid, B7S1 polypeptides, and antibodies that bind B7S1 polypeptides. B7S1 sequences can be used, e.g., to screen for modulators of B7S1 activity. Modulators, e.g., antibodies or small molecules, can be used for the treatment of disease that involve an immune response. ... 07/21/05 - 20050158308 - Heh4 molecules and uses thereof The present invention provides HEH4 polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing HEH4 polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated ... 07/21/05 - 20050158307 - Methods and compositions for treating autoimmune diseases or conditions The present invention relates to methods of treating immune disorders, particularly autoimmune and inflammatory disorders such as rheumatoid arthritis, and methods of producing antibodies for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies that specifically bind to NKG2D receptors present on ... 06/30/05 - 20050142132 - Prevention and treatment of amyloidogenic disease The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. ... 06/30/05 - 20050142131 - Humanized antibodies Humanized forms of mouse antibody 10D5 that retain the binding properties of mouse 10D5 are disclosed. Also disclosed closed are processes for making the humanized antibody, intermediates for making the humanized antibodies, including, nucleotide sequences, vectors, transformed host cells, and methods of using the humanized antibody to treat, prevent, alleviate, ... 06/16/05 - 20050129680 - Antimicrobial activity of antibodies The invention provides compositions having antibodies that can generate reactive oxygen species when exposed to singlet oxygen, as well as methods of using the compositions, for example, to treat microbial infections. ... 06/09/05 - 20050123536 - Treatment of immunological disorders using anti-dc30 antibodies The present invention relates to methods for the treatment of immunological disorders other than cancer, comprising administering proteins characterized by their ability to bind to CD30 and exert a cytostatic or cytotoxic effect on an activated lymphocyte. Such proteins include monoclonal antibodies AC10 and IleFi1. AC10 and HeFi-1 derivatives, and ... 06/02/05 - 20050118167 - Parenteral pharmaceutical composition containing humanized monoclonal antibody fragment and stabilizing method thereof This invention relates to a parenteral pharmaceutical composition which comprises a humanized monoclonal antibody fragment, a nonionic surface active agent and saccharides, wherein its pH is weakly acidic. The invention also relates to a method for the stabilization of a humanized antibody fragment, which comprises formulating a nonionic surface active ... 06/02/05 - 20050118166 - Therapeutic applications for the anti-t-bam (cd40-1) monoclonal antibody 5c8 Activation of cells bearing CD40 on their cell surface by CD40 ligand is inhibited by contacting the cells with an agent capable of inhibiting interaction between CD40 ligand and the cells, in an amount effective to inhibit activation of the cells. Activation of cells bearing CD40 on their surface by ... 06/02/05 - 20050118165 - Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor In a wide variety of human solid tumors, an aggressive, metastatic phenotype and poor clinical prognosis are associated with expression of the receptor tyrosine kinase. Met and its agonist ligand HGF. Disclosed herein are (a) mAbs and hybridoma cell lines that produce them, which mAbs antibodies are specific for Met ... ### FreshPatents.com Support |